{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:19:49Z","timestamp":1768637989112,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102212","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:31:56Z","timestamp":1724448716000},"page":"102212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-3156","authenticated-orcid":false,"given":"Keita","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Sakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Tei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-947X","authenticated-orcid":false,"given":"Kazuhiro","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Yoshihiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chietaka","family":"Ohmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Akao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102212_bib0001","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0002","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2000.18.9.1921","article-title":"Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer","volume":"18","author":"Kaufman","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0003","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0004","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0005","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.eururo.2015.07.042","article-title":"Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma","volume":"69","author":"Sonpavde","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102212_bib0006","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/iju.12532","article-title":"Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma","volume":"21","author":"Mitsuzuka","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102212_bib0007","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/jjco\/hyz084","article-title":"Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma","volume":"49","author":"Abe","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0008","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102212_bib0009","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0011","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102212_bib0012","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the javelin bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0013","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.juro.2018.07.035","article-title":"Impact of the number of cycles of platinum based first line chemotherapy for advanced urothelial carcinoma","volume":"200","author":"Sonpavde","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102212_bib0014","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1002\/cam4.3863","article-title":"Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: analysis of a Japanese nationwide cohort","volume":"10","author":"Ito","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2024.102212_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113141","article-title":"Pathogenesis of platinum-induced peripheral neurotoxicity: insights from preclinical studies","volume":"325","author":"Calls","year":"2020","journal-title":"Exp Neurol"},{"key":"10.1016\/j.clgc.2024.102212_bib0016","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/iju.14987","article-title":"Anticancer maintenance chemotherapy prolonged prognosis of metastatic urothelial carcinoma patients: a single institute retrospective study using propensity score matching","volume":"29","author":"Yamamoto","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102212_bib0017","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.7150\/jca.57413","article-title":"Network meta-analysis comparing efficacy, safety and tolerability of anti-pd-1\/pd-l1 antibodies in solid cancers","volume":"12","author":"Al-Showbaki","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.clgc.2024.102212_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001246","article-title":"Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis","volume":"8","author":"Apolo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2024.102212_bib0019","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.21873\/anticanres.16922","article-title":"Comparison of oncological outcomes of pembrolizumab as second-line therapy and maintenance avelumab therapy in advanced urothelial carcinoma after platinum-based chemotherapy","volume":"44","author":"Shindo","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2024.102212_bib0020","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102212_bib0021","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00432-024-05717-2","article-title":"Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan","volume":"150","author":"Hirasawa","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0022","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/1759-7714.13867","article-title":"Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Brito","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clgc.2024.102212_bib0023","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s12094-020-02316-8","article-title":"The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials","volume":"22","author":"Zhang","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clgc.2024.102212_bib0024","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2024.102212_bib0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102212_bib0026","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:43:53Z","timestamp":1746463433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324001824"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102212","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102212"}}